ClinicalTrials.gg
CompletedNCT02100917Updated Feb 10, 2015

Bioequivalence Study Evaluating the Pharmacokinetics of DMB-3111 and Trastuzumab in Healthy Japanese Male Adults

A Phase 1 interventional study of DMB-3111 and trastuzumab in Healthy Volunteer, sponsored by Meiji Seika Pharma Co., Ltd.. Completed at 1 site in Japan. Open to male participants aged 20 Years to 39 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2015-02-10.

Sponsored by Meiji Seika Pharma Co., Ltd. · Phase 1 and Interventional

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
70
Allocation
Randomized
Ages
20 Years to 39 Years
Sex
Male
01

Study summary

This study is a randomized Trastuzumab-controlled double-blind parallel-group study.

02

Conditions studied

  • Healthy Volunteer

Browse trials for

Keywords

  • Bioequivalence
  • Biosimilarity
  • Similarity
  • Pharmacokinetics
  • Phase I
  • Trastuzumab
  • Healthy Male Volunteers
  • Single-dose
  • HER-2
  • Oncology
03

In context

Neoplasms

10,826 studies on the registry are indexed under Neoplasms; 2,325 are open to participants now.

This study's enrollment of 70 is above the median of 60 across 7,706 interventional studies indexed under Neoplasms.

Browse Neoplasms studies →

Lead sponsor

Meiji Seika Pharma Co., Ltd. is the lead sponsor of 10 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
20 Years to 39 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Healthy Japanese male adults
  2. (BMI) between 17.6 and 26.4 kg/m² at the time of screening BMI = Body Weight (kg)/[Height (m)]²
  3. The individual who freely consents to participate after receiving a detailed explanation of the clinical study and completely understanding thereof, and who has capacity to follow precautions and provide written consent.

Exclusion criteria

Exclusion Criteria:

  1. History of to components of Trastuzumab or diphenhydramine or any other drug
  2. Use of any ethical drug within 2 weeks before product administration or any over-the-counter drug within 1 week before investigational product administration that would affect study participation in the opinion of the investigator or subinvestigators (except for diphenhydramine, which will be used concomitantly in the present clinical trial and any drug applied locally and having no systemic actions)
  3. History of allergic symptoms such as bronchial asthma and urticaria that would affect study participation in the opinion of the investigator or subinvestigators
  4. History of cardiac disorders, hypertension, coronary artery disease (e.g., myocardial infarction, angina), and/or vascular disorder; ongoing palpitations, shortness of breath, and/or tachycardia
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
70 participants (actual)

Study arms

  • Experimental
    DMB-3111

    6 mg/kg is once given in intravenous drip infusion taking 90 min

    Drug: DMB-3111

  • Active comparator
    trastuzumab

    6 mg/kg is once given in intravenous drip infusion taking 90 min

    Drug: trastuzumab

Interventions

06

What researchers measure

Primary outcomes

  1. Area Under the Concentration-Time (AUC)

    Time frame: Day1-71

  2. Maximum observed serum concentration (Cmax)

    Time frame: Day1-71

Secondary outcomes

  1. Area under the concentration-time curve (AUC) from 0 to time of the last measurable concentration

    Time frame: Day1-71

  2. Area under the concentration-time curve (AUC) from 0 to infinity

    Time frame: Day1-71

  3. Time to reach the peak concentration (tmax)

    Time frame: Day1-71

  4. Mean residence time (MRT) from 0 to final sampling time point

    Time frame: Day1-71

  5. Mean residence time (MRT) from 0 to infinity

    Time frame: Day1-71

  6. elimination rate constant (kel)

    Time frame: Day1-71

  7. Elimination half life (t1/2)

    Time frame: Day1-71

  8. Clearance (CL)

    Time frame: Day1-71

  9. Incidence of adverse events

    Time frame: Day1-71

Other outcomes

  1. Incidence of anti-trastuzumab antibodies (ADAs)

    Time frame: Day1-71

07

Study locations

1 site
  • Fukuoka, Japan
08

References and documents

Publications

  • Morita J, Tanaka M, Nomoto M, Matsuki S, Tsuru T, Matsuguma K, Shiramoto M. Pharmacokinetic Bioequivalence, Safety, and Immunogenicity of DMB-3111, a Trastuzumab Biosimilar, and Trastuzumab in Healthy Japanese Adult Males: Results of a Randomized Trial. BioDrugs. 2016 Feb;30(1):17-25. doi: 10.1007/s40259-015-0153-2. PubMed 26691837 ↗
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jan 2014, a primary completion of May 2014 and a completion of Dec 2014. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 27, 2014
First posted
Apr 1, 2014
Start
Jan 2014
Primary completionActual
May 2014
CompletionActual
Dec 2014
Last update
Feb 10, 2015
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 10, 2015, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02100917
Lead sponsor
Meiji Seika Pharma Co., Ltd.
Responsible party
Sponsor
First posted
Apr 1, 2014
Start date
Jan 2014
Primary completion
May 2014
Completion
Dec 2014
Last update
Feb 10, 2015

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Trastuzumab

Start the discussion